Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of AbSci.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
AbSci
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
101 E 6th Street, Suite 300, Vancouver, WA 98660
Telephone
Telephone
360-949-1041

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 04, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The partnership combines Absci’s de novo AI Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.


Lead Product(s): De novo Therapeutic Antibody

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: Almirall

Deal Size: $650.0 million Upfront Cash: Undisclosed

Deal Type: Partnership November 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the collaboration, Absci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments.


Lead Product(s): Enzyme

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Undisclosed Upfront Cash: $610.0 million

Deal Type: Collaboration January 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement AbSci will prepare the hAFP producing E. coli strain for transfer to Alpha Cancer Technologies' CMO of choice for commercial production.


Lead Product(s): Recombinant Human Alpha-fetoprotein

Therapeutic Area: Immunology Product Name: ACT-101

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Alpha Cancer Technologies

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 22, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY